Access Consortium begins Promise Pilot priority review
If you study pharmacy, policy or global health, here’s a live case of cooperation in action. Five medicines regulators have introduced a shared route to decide when a new drug should get a faster review. The UK regulator’s news page was refreshed on 10 April 2026 to point to the latest guidance on this pilot, called Promise.(gov.uk)
Access is a collaboration between the UK’s Medicines and Healthcare products Regulatory Agency, Australia’s Therapeutic Goods Administration, Health Canada, Singapore’s Health Sciences Authority and Swissmedic. They look at applications together, but each country still makes its own call. Promise is their pilot pathway for priority cases, built to apply a single set of expectations up front.(assets.publishing.service.gov.uk)
What counts as a priority case here is tight by design. To use Promise, a medicine must diagnose, prevent or treat a serious, life‑threatening or severely disabling condition, and for the specific use proposed there can’t already be a treatment registered and on the market in any of the five countries. The MHRA confirmed these criteria when announcing the pathway and has since updated the page link.(gov.uk)
From a developer’s point of view, the early step is a single evidence package that argues for priority review. One regulator leads the assessment, the others peer‑review, and together they try to reach a consensus on priority status. If some say yes and others don’t, those that agree can still run the fast route while the rest use the standard shared process.(assets.publishing.service.gov.uk)
Timelines are being aligned so you are not guessing what happens when. Applicants are asked to signal interest roughly six months before filing, there is a short screening stage before the formal ‘Day 0’ start of review, and under priority review questions can be sent as the evaluation progresses rather than bundled at the end. That keeps momentum and reduces late surprises.(assets.publishing.service.gov.uk)
A key learning point for essays and exams: this is cooperation, not a supranational approval. Each country makes a sovereign decision, and an approval or refusal in one place does not bind the others. Labels can still differ by country, and there is no legal right of appeal within the pilot itself; national routes remain available.(assets.publishing.service.gov.uk)
Why this matters for patients is time. Previous Access collaborations showed that coordinating work across these same agencies cut the lag between first and later submissions by months; one peer‑reviewed analysis reported median reductions of around 257–374 days, depending on the regulator. Promise aims to apply that spirit to the toughest, no‑treatment cases.(pmc.ncbi.nlm.nih.gov)
If you are mapping this for a coursework brief, describe it in plain steps: early conversations with each regulator, a joint request arguing for priority, agreement on who leads which scientific modules, then a coordinated review. The dossier is shared, but Module 1 still follows each country’s rules, and everyone agrees an evaluation plan with clear milestones.(assets.publishing.service.gov.uk)
A quick classroom FAQ in sentence form helps. Is this only for brand‑new drugs? It applies to new active substances and, in some cases, new indications, provided the strict criteria are met. Does it replace national fast‑track routes? No-if priority status is not granted under Promise, companies can still pursue national priority or reconsideration options.(assets.publishing.service.gov.uk)
What to watch in 2026 is whether the pilot’s scope evolves. The MHRA notes the pathway will be reviewed after the pilot phase, and its page was last updated on 10 April 2026 to link the latest operational guide, currently Version 1.2 (effective 1 June 2025). If criteria or timelines change, those documents will show it first.(gov.uk)